Pharma BD Deal Intelligence
Pfizer won Metsera in a bidding war, raising its offer to $65.60/share cash plus CVRs after Novo Nordisk's $8.5B rival bid collapsed on FTC antitrust risk, though Phase 2b data showing 10-12.3% weight loss came with nearly 10% discontinuation.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer wins the bidding war for Metsera with a $10 billion offer. Metsera stated Novo Nordisk's proposal presented 'unacceptably high legal and regulatory…
Pfizer's First Weight-Loss Data After Metsera Buy 'Look Competitive'. BMO Capital Markets assessed that Pfizer's weight-loss results look competitive with…
Pfizer 10-Q for quarter ended March 29, 2026 reflects the Metsera acquisition: ~$7B upfront cash consideration plus contingent value rights; guided to reduce…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Pfizer agreed (Sept 22, 2025) to acquire Metsera initially at $47.50/share cash plus CVR up to $22.50/share (~$10B total). After Novo Nordisk launched a rival ~$8.5B bid in October, Pfizer raised its offer; the amended merger (Nov 7, 2025) set $65.60/share cash upfront (~$7.0B enterprise value) plus a CVR of up to $20.65/share ($4.60 + $6.40 + $9.65 across three clinical/regulatory milestones), keeping the up-to total near $10B. Metsera cited FTC antitrust risk in Novos bid; Pfizer prevailed and closed Nov 13, 2025. The deal gives Pfizer Metseras next-generation obesity portfolio led by ultra-long-acting injectable GLP-1 MET-097i and amylin analog MET-233i.
100M US cases/yr · $66.4B Global GLP-1 receptor agonist market 2025 (USD MM) · 5000 Leerink peak sales projection for Metsera assets combined (USD MM)
Obesity is a chronic metabolic disease defined by BMI >=30 kg/m², with severe obesity at BMI >=40. Per CDC NHANES data (August 2021-August 2023), US adult obesity prevalence is 40.3%, with severe obesity at 9.4% — translating to approximately 100 million US adults with obesity and ~24 million with severe obesity. Middle-aged adults (40-59) have the highest prevalence (~46%). Obesity is associated with type 2 diabetes, cardiovascular disease, NAFLD/MASH, obstructive sleep apnea, and at least 13 obesity-associated cancers, driving direct US medical costs estimated above $170 billion annually. The introduction of GLP-1 receptor agonists — semaglutide (Wegovy/Ozempic, Novo Nordisk) and tirzepatide (Zepbound/Mounjaro, Eli Lilly) — has transformed obesity pharmacotherapy with 15-22% weight-loss efficacy, creating the largest rapidly scaling market in pharma. Metsera's next-generation portfolio pursues long-acting injectable and oral GLP-1/amylin mechanisms to improve dosing convenience (monthly injection) and potentially tolerability versus weekly GLP-1 incumbents. Pfizer acquired Metsera amid the largest bidding war of 2025, outlasting Novo Nordisk's competing $8.5 billion offer with FTC clearance and a November 2025 close.
The obesity pharmacotherapy market is dominated by incretin-targeted peptides with next-generation oral and long-acting formulations as the key competitive axes. GLP-1 monotherapy: Wegovy (semaglutide, Novo Nordisk) — weekly injection, 15% weight loss; Ozempic (T2D label). GLP-1/GIP dual agonist: Zepbound (tirzepatide, Eli Lilly) — weekly, 20-22% weight loss, market leader on efficacy. Next-generation injectable incretins: Pfizer/Metsera's MET-097i (monthly GLP-1, Phase 2b 14.1% weight loss), Novo Nordisk's CagriSema (semaglutide + cagrilintide amylin analog, Phase 3), Lilly's retatrutide (GLP-1/GIP/glucagon triple agonist, Phase 3 ~24% weight loss). Amylin analogs: MET-233i (Metsera, oral amylin), cagrilintide (Novo Nordisk). Oral GLP-1: Rybelsus (oral semaglutide, Novo), orforglipron (Lilly, Phase 3 oral GLP-1). Pipeline challengers: Viking Therapeutics (VK2735 dual GLP-1/GIP oral/SC), Structure Therapeutics (GSBR-1290 oral). Metsera's positioning centers on monthly dosing and amylin combinations to address adherence gaps in a market where Lilly's retatrutide threatens efficacy leadership.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Metsera, Inc. (this deal) | 2025 | $10.0B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2025 deals · Pfizer Inc. deals · Metabolic deals